TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ocumension Therapeutics ( (HK:1477) ) has shared an update.
Ocumension Therapeutics announced that its key drug candidate, OT-301 (NCX 470), has achieved the primary endpoint of non-inferiority compared to latanoprost in its second phase III clinical trial, known as the Denali trial. This success marks a significant step towards new drug approval in China, demonstrating OT-301’s favorable safety profile and superior intraocular pressure reduction. The trial involved 696 patients across the United States and China, further solidifying Ocumension’s position in the ophthalmic drug market and potentially impacting stakeholders positively by expanding its product offerings in the region.
The most recent analyst rating on (HK:1477) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is a pharmaceutical company involved in the development of ophthalmic drugs. The company focuses on creating innovative treatments for eye diseases, with a market emphasis on Greater China, Korea, and Southeast Asia.
Average Trading Volume: 8,673,592
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.83B
For a thorough assessment of 1477 stock, go to TipRanks’ Stock Analysis page.